Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Rating of “Moderate Buy” by Brokerages

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) has received a consensus recommendation of “Moderate Buy” from the twelve research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $61.00.

IMCR has been the topic of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 target price on shares of Immunocore in a report on Wednesday, October 22nd. Wall Street Zen raised Immunocore from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Guggenheim initiated coverage on Immunocore in a report on Thursday, September 18th. They set a “neutral” rating on the stock. Wells Fargo & Company initiated coverage on shares of Immunocore in a report on Friday, October 31st. They issued an “overweight” rating and a $60.00 target price for the company. Finally, Morgan Stanley upped their price target on shares of Immunocore from $34.00 to $36.00 and gave the company an “equal weight” rating in a research note on Monday, November 10th.

Immunocore Price Performance

IMCR stock opened at $39.87 on Wednesday. Immunocore has a one year low of $23.15 and a one year high of $40.21. The company’s fifty day moving average price is $34.33 and its 200-day moving average price is $33.82. The company has a debt-to-equity ratio of 0.99, a quick ratio of 5.97 and a current ratio of 6.00. The company has a market capitalization of $2.01 billion, a PE ratio of -69.95 and a beta of 0.78.

Immunocore (NASDAQ:IMCR) last posted its earnings results on Thursday, November 6th. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.32. The company had revenue of $103.69 million during the quarter, compared to analysts’ expectations of $137.29 million. Immunocore had a negative net margin of 7.70% and a negative return on equity of 7.67%. Immunocore’s quarterly revenue was up 29.2% on a year-over-year basis. During the same period last year, the company posted $0.17 earnings per share. On average, equities analysts anticipate that Immunocore will post -0.94 EPS for the current fiscal year.

Insider Activity

In related news, insider David M. Berman sold 22,532 shares of the stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $35.67, for a total value of $803,716.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 10.40% of the company’s stock.

Institutional Investors Weigh In On Immunocore

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its holdings in shares of Immunocore by 51.6% in the 3rd quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock worth $33,000 after purchasing an additional 311 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Immunocore by 4,696.3% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company’s stock worth $41,000 after acquiring an additional 1,268 shares during the last quarter. Elevation Point Wealth Partners LLC bought a new stake in shares of Immunocore in the 2nd quarter worth about $42,000. Osaic Holdings Inc. boosted its stake in shares of Immunocore by 117.4% during the 2nd quarter. Osaic Holdings Inc. now owns 3,148 shares of the company’s stock worth $97,000 after purchasing an additional 1,700 shares during the period. Finally, State of Tennessee Department of Treasury bought a new position in Immunocore during the 2nd quarter valued at about $132,000. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.